z-logo
Premium
Serum markers of collagen synthesis and degradation in acute respiratory failure patients
Author(s) -
OKKONEN M.,
GÄDDNÄS F.,
PETTILÄ V.,
LAURILA J.,
OHTONEN P.,
RISTELI J.,
LINKO R.,
ALAKOKKO T.
Publication year - 2013
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/aas.12182
Subject(s) - medicine , procollagen peptidase , type i collagen , population , respiratory distress , respiratory system , gastroenterology , endocrinology , surgery , environmental health
Background Procollagen‐derived propeptides reflect the rate of collagen synthesis and type I cross‐linked collagen telopeptides ( ICTP ) collagen I degradation. We studied the collagen metabolism to find out if changes seen in acute respiratory distress syndrome patients are observed in patients with acute respiratory failure ( ARF ), and whether multiple organ dysfunction ( MOD ) has impact on it. Methods ARF patients with prolonged hospitalisation at least 21 days were included to the study. Blood samples for serum procollagen aminoterminal propeptide I ( PINP ) and III ( PIIINP ), and ICTP measurements were collected at study admission (day 0) and on days 2, 7, and 21. Results The study population comprised 68 patients. Forty‐three patients (63%) developed MOD during the first week. PIIINP levels increased in all patients over time. The increase was slightly more pronounced in patients with MOD . During the first week, the synthesis of PIIINP increased more than PINP , and PINP degradation exceeded its production. By day 21, the balance of collagen metabolites returned to baseline. Conclusion The collagen metabolism was altered in ARF patients. The first week was dominated by degradation of type I collagen and production of type III collagen, but by day 21, the collagen composition returned to more stable form.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here